The ascendancy of Viagra and its effect on the drug landscape presents a complex question for shareholders. While the initial sales figures were impressive, the exclusivity has lapsed, leading to a deluge of off-brand alternatives that are chipping away at profit. Furthermore, the sector is facing issues related to aging trends and evolving healthc